FLAME - First Line olAparib Maintenance bEyond BRCA An Observational Cohort Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy Beyond BRCA Mutant Status in Newly Diagnosed Advanced Ovarian Cancer
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Olaparib (Primary) ; Antineoplastics
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms FLAME
- Sponsors AstraZeneca
Most Recent Events
- 29 Nov 2023 Status changed from recruiting to completed.
- 03 Oct 2023 Planned End Date changed from 15 Sep 2023 to 16 Oct 2023.
- 03 Oct 2023 Planned primary completion date changed from 15 Sep 2023 to 16 Oct 2023.